The US Food and Drug Administration and Drug Enforcement Administration have issued joint warning letters to four online networks which allegedly sell unapproved and misbranded versions of medicines.
An independent parliamentary report has today, September 27, revealed that the UK’s health ministry remains unsure whether the country’s health service can fully withstand the impact of a no-deal Brexit next month.
China’s drug pricing overhaul has seen the average cost of drugs drop by more than half, the country’s Joint Procurement Office announced this week.
Jeremy Corbyn, leader of the UK Labour Party, has pledged to create a publicly-owned drugs manufacturer and use compulsory licensing to sell generic, lower priced versions of drugs to the country’s National Health Service.
A group of senators has urged the US Federal Trade Commission to closely scrutinise mergers in the pharmaceutical industry, which it said “increase competition issues and stifle innovation”.
A US judge dismissed antitrust counterclaims brought against Allergan and Duke University earlier this week, in a lawsuit the pair filed against generics maker Akorn.
This week at the AIPPI World Congress 2019, counsel discussed how supplementary protection certificates and patent term extension regulations differ across jurisdictions.
A district court has upped Vectura’s award of $89.7 million in damages by $10m, after a jury trial earlier this year found that GlaxoSmithKline has willfully infringed one of its patents.
Innovative Medicines Canada, an association that represents drugmakers in Canada, has challenged the overhaul of Canada’s drug-pricing regime.
The US Court of Appeals for the Federal Circuit has ruled that claims in an Allergan patent detailing the results of a glaucoma treatment are material to its patentability, after an unsuccessful invalidation appeal brought by Sandoz.